SSNIs 和 SNRIs 在广泛性焦虑障碍治疗中的应用

Generalised anxiety disorder (GAD) is a prevalent condition that significantly impairs quality of life and is associated with substantial economic costs and increased use of healthcare resources. GAD is associated with numerous comorbidities, particularly psychiatric ones, which complicate therapeutic management and increase the severity and burden of the condition. Serotonin and norepinephrine reuptake inhibitors (SNRIs) are among the first-line pharmacological options for managing GAD. Their use is supported by efficacy and a favourable safety profile demonstrated in randomised clinical tria